How to buy Genetron stock - 22 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Genetron stock

Own Genetron stock in just a few minutes.

Genetron Holdings Limited is a diagnostics & research business based in the US. Genetron shares (GTH) are listed on the NASDAQ and all prices are listed in US Dollars. Genetron employs 799 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Genetron

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GTH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Genetron share price

Use our graph to track the performance of GTH stocks over time.

Genetron shares at a glance

Information last updated 2021-04-16.
52-week range$9.03 - $31.54
50-day moving average $22.03
200-day moving average $17.51
Wall St. target price$25.52
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.56

Buy Genetron shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Genetron stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Genetron financials

Revenue TTM $424.5 million
Gross profit TTM $260.2 million
Return on assets TTM -12.56%
Return on equity TTM -2433.48%
Profit margin 0%
Book value N/A
Market capitalisation $1.8 billion

TTM: trailing 12 months

Shorting Genetron shares

There are currently 446,959 Genetron shares held short by investors – that's known as Genetron's "short interest". This figure is 62.6% up from 274,936 last month.

There are a few different ways that this level of interest in shorting Genetron shares can be evaluated.

Genetron's "short interest ratio" (SIR)

Genetron's "short interest ratio" (SIR) is the quantity of Genetron shares currently shorted divided by the average quantity of Genetron shares traded daily (recently around 417718.69158879). Genetron's SIR currently stands at 1.07. In other words for every 100,000 Genetron shares traded daily on the market, roughly 1070 shares are currently held short.

However Genetron's short interest can also be evaluated against the total number of Genetron shares, or, against the total number of tradable Genetron shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genetron's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Genetron shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Genetron shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genetron.

Find out more about how you can short Genetron stock.

Genetron share dividends

We're not expecting Genetron to pay a dividend over the next 12 months.

Genetron overview

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer. It also provides in-vitro diagnostics products, including 8-gene Lung Cancer Assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1/TERT gene assays for glioma; GENETRON S5, a semiconductor sequencer used in the field of gene detection; and Genetron S2000 that enables gene panel sequencing. In addition, the company develops ctDNA Lung Cancer assay for mutations in the epidermal growth factor receptor gene. It also offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a partnership agreement with dMed Biopharmaceutical for new drug research and development in the field of oncology. The company was founded in 2015 and is headquartered in Beijing, the People's Republic of China.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site